Synagis TM
Listen to the Pronunciation:
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: palivizumab
Brand name
(ARTG)
: SYNAGIS palivizumab (rmc) 50 mg / 0.5 mL solution for injection vialConsumer Medicine Information (CMI)
Read the CMI leaflet for facts you need to know before, during and after taking your medicine.
Listen to the audio transcription of the CMI leaflet.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
(ARTG)
Synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (CHD). (See Clinical Trials).
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Intramuscular
- Clear or slightly opalescent, sterile solution.
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Store in Original Container
- Shelf lifetime is 3 Years.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 1 pack
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
